LTC4 Production by Eosinophils in Asthmatic Subjects with Alternative Forms of Alox-5 Core Promoter
- 144 Downloads
Pharmacogenetics is the use of genetic information to determine who will (or will not) respond to a given treatment. In order to have a pharmacogenetic basis, there should be variability in the treatment response. Although there are data on the variability of the treatment response to all classes of medications that are used in the treatment of asthma- i.e., glucocorticoids, teophyllin, β2 agonists and leukotriene modifiers- pharmacogenetic associations have been described only for β2 agonists and leukotriene modifiers .
KeywordsBinding Motif Asthmatic Subject Asthmatic Individual Pharmacogenetic Association LTC4 Production
Unable to display preview. Download preview PDF.
- 2.Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75–80.PubMedGoogle Scholar
- 5.In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, De Sanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ, Segal A, Tinkleman D, Drazen JM. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130–1137.PubMedCrossRefGoogle Scholar